XML 52 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Agreements - Summary of Agreement (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 5 Months Ended 9 Months Ended
Jul. 31, 2018
USD ($)
May 31, 2018
USD ($)
item
Jul. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
item
May 31, 2016
USD ($)
May 31, 2015
USD ($)
item
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
item
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Collaboration and other research and development revenues             $ 14,519       $ 25,818    
Revenue type             us-gaap:ServiceMember       us-gaap:ServiceMember    
Research and development             $ 17,443   $ 20,396   $ 71,460 $ 56,735  
Deferred revenue             112,825     $ 112,825 112,825   $ 107,963
Deferred revenue, long-term             104,100     104,100 104,100   94,725
Accounts receivable             43     43 43   679
Juno Therapeutics                          
Allocable arrangement consideration - R&D Services Unit of Accounting             15,800     15,800 15,800    
Allocable arrangement consideration - Development and Commercialization License for the first research area             3,600     3,600 3,600    
Allocable arrangement consideration - Development and Commercialization License for the second research area             6,000     6,000 6,000    
Allocable arrangement consideration - Development and Commercialization License for the third research area             100     100 100    
Allocable arrangement consideration - Development and Commercialization License for the fourth research area             18,300     18,300 18,300    
Allocable arrangement consideration - First additional Development and Commercialization License for the first research area             300     300 300    
Allocable arrangement consideration - Second additional Development and commercialization license for the first research area             200     200 200    
Allocable arrangement consideration - Third additional Development and commercialization license for the first research area             100     100 100    
Allocable arrangement consideration - First additional Development and commercialization license for the second research area             800     800 800    
Allocable arrangement consideration - Second additional Development and commercialization license for the second research area             500     500 500    
Allocable arrangement consideration - Third additional Development and commercialization license for the second research area             300     300 300    
Collaboration and other research and development revenues             $ 700   $ 3,100   $ 5,200 $ 4,400  
Revenue type             us-gaap:ServiceMember   us-gaap:ServiceMember   us-gaap:ServiceMember us-gaap:ServiceMember  
Revenue recognized related to milestone payment                 $ 2,500     $ 2,500  
Additional revenue related to cumulative catch-up adjustments                     $ 3,000    
Deferred revenue             $ 33,200     33,200 33,200   26,400
Deferred revenue, long-term             32,600     32,600 32,600   26,400
Accounts receivable             0     0 $ 0   500
Allergan                          
Number of additional licenses | item                     2    
Potential development milestone payments             8,000     8,000 $ 8,000    
One time payment to acquire the license             25,000     25,000 $ 25,000    
Number of days in which payment to be made                     45 days    
Allergan | Maximum                          
Potential development milestone payments             42,000     42,000 $ 42,000    
Potential regulatory and commercial milestone payments             75,000     75,000 75,000    
Potential commercial milestone payments             90,000     90,000 90,000    
Collaboration and License Agreement | Juno Therapeutics                          
Number of research areas | item           3              
Agreement term           5 years              
Extensions | item           2              
Extension period           1 year              
Upfront fee received           $ 25,000              
Potential research and development funding           $ 22,000              
Number of additional licenses | item           3              
Potential fee receivable for each gene target licensed           $ 2,500              
Potential development milestone payments           77,500              
Potential regulatory milestone payments           80,000              
Potential commercial milestone payments           $ 75,000              
Milestone payment received under license agreement     $ 2,500   $ 2,500                
Collaboration and License Agreement | Allergan                          
Research and development             2,800       2,800    
Research and development expense             1,100       1,100    
Amended Collaboration and License Agreement | Juno Therapeutics                          
Number of research areas | item   4                      
Additional upfront fee received   $ 5,000                      
Number of milestones related to technical progress | item   2                      
Milestone payment receivable related to technical progress   $ 2,500                      
Potential development milestone payments   80,000                      
Potential regulatory milestone payments   $ 80,000                      
Number of milestone payment received | item   2                      
Milestone payment received under license agreement   $ 2,500                      
Next possible milestone payment             2,500     2,500 2,500    
Collaboration and other research and development revenues                   0      
Additional revenue related to cumulative catch-up adjustments                   0      
Research and development                     1,700    
Strategic Alliance | Allergan                          
Agreement term       7 years                  
Extension period       1 year                  
Upfront fee received       $ 90,000                  
Number of Collaboration Development Programs | item       5                  
Number of Committee Members | item       3                  
Option exercise price per CDP       $ 15,000                  
Extension fee for Initial Option Period       5,000                  
Option exercise price for development and commercialization license       $ 22,500                  
Collaboration and other research and development revenues             $ 13,800   $ 3,200   $ 16,700 $ 5,600  
Revenue type             us-gaap:ServiceMember   us-gaap:ServiceMember   us-gaap:ServiceMember us-gaap:ServiceMember  
Deferred revenue             $ 79,100     79,100 $ 79,100   81,200
Deferred revenue, long-term             71,500     71,500 $ 71,500   $ 68,300
Contract termination notice                     90 days    
Option exercise payment received $ 15,000                        
Strategic Alliance | Allergan | Maximum                          
Extension period       10 years                  
Sponsored Research Agreement | Broad                          
First research funding amount due and payable             5,000     5,000 $ 5,000    
Second research funding amount due and payable             7,500     7,500 7,500    
Research and development               $ 12,500          
Sponsored Research Agreement | Broad | Maximum                          
Research funding amount due and payable             125,000     $ 125,000 125,000    
License Agreement | Allergan                          
Research and development             2,300   $ 6,700   2,300 $ 14,100  
License Agreement | Beam Therapeutics, Inc                          
Collaboration and other research and development revenues             $ 100       $ 4,000    
Revenue type                     us-gaap:ServiceMember    
Non-cash consideration aggregate fair value received   $ 3,600                      
Contract termination notice   90 days